Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Cash & Equivalents (2019 - 2025)

Bioadaptives' Cash & Equivalents history spans 7 years, with the latest figure at $158445.0 for Q4 2025.

  • Quarterly results put Cash & Equivalents at $158445.0 for Q4 2025, up 15.26% from a year ago — trailing twelve months through Dec 2025 was $158445.0 (up 15.26% YoY), and the annual figure for FY2025 was $158445.0, up 15.26%.
  • Cash & Equivalents for Q4 2025 was $158445.0 at Bioadaptives, up from $59273.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $210582.0 in Q2 2025 to a low of $235.0 in Q2 2024.
  • The 5-year median for Cash & Equivalents is $50119.5 (2022), against an average of $65808.0.
  • The sharpest move saw Cash & Equivalents plummeted 99.41% in 2024, then skyrocketed 89509.36% in 2025.
  • Year by year, Cash & Equivalents stood at $82936.0 in 2021, then crashed by 69.37% to $25405.0 in 2022, then soared by 139.23% to $60776.0 in 2023, then surged by 126.19% to $137470.0 in 2024, then rose by 15.26% to $158445.0 in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $158445.0, $59273.0, and $210582.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.